The Immunoadoptive Cell Therapy Private Limited (ImmunoACT), based in Mumbai, India, on October 13, 2023, announced the Central Drugs Standard Control Organization (CDSCO)’s approval for the use of the country’s first chimeric antigen receptor (CAR-T) cell therapy for the treating relapsed-refractory B-cell lymphoma and leukemia.
Trending
- BSUTH offers complete IVF for N700,000
- Lagos arrests 27 for vandalising Festac-Alakija bridge
- NGO trains 60,000 girls in STEM
- Stakeholders: Tribal marks, bowlegs not disabilities
- ActionAid calls for stronger collaboration on women’s empowerment
- Neurosurgeon outlines key options for managing hydrocephalus
- Energy costs remain major inflation driver despite easing concerns — CBN
- Fintiri assures new NYSC camp ready for next batch
